Lymphoma, T-Cell Clinical Trials

9 recruiting

Lymphoma, T-Cell Trials at a Glance

11 actively recruiting trials for lymphoma, t-cell are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in New York, Boston, and Chicago. Lead sponsors running lymphoma, t-cell studies include Institute of Hematology & Blood Diseases Hospital, China, Corvus Pharmaceuticals, Inc., and Columbia University.

Browse lymphoma, t-cell trials by phase

Treatments under study

About Lymphoma, T-Cell Clinical Trials

Looking for clinical trials for Lymphoma, T-Cell? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lymphoma, T-Cell trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lymphoma, T-Cell clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 1Phase 2

A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Lymphoma, T-CellLymphoma, B-Cell
Step Pharma, SAS180 enrolled15 locationsNCT05463263
Recruiting
Phase 3

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Lymphoma, T-CellPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell Lymphoma+4 more
Corvus Pharmaceuticals, Inc.150 enrolled34 locationsNCT06561048
Recruiting
Phase 2

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Lymphoma, T-CellT-LGL LeukemiaNK-LGL Leukemia+7 more
Institute of Hematology & Blood Diseases Hospital, China48 enrolled2 locationsNCT06716658
Recruiting

Tissue Repository: CTCL Collection Protocol

Lymphomatoid PapulosisLymphoma, T-Cell, CutaneousSézary Syndrome
Columbia University400 enrolled1 locationNCT02840747
Recruiting
Phase 2

MB-105 in Patients With CD5 Positive T-cell Lymphoma

Lymphoma, T-Cell
March Biosciences Inc46 enrolled12 locationsNCT06534060
Recruiting
Phase 3

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Lymphoma, T-Cell, Peripheral
Chipscreen Biosciences, Ltd.224 enrolled1 locationNCT06947967
Recruiting
Phase 2

PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Lymphoma, T-CellT-LGL LeukemiaNK-LGL Leukemia
Institute of Hematology & Blood Diseases Hospital, China51 enrolled1 locationNCT06530550
Recruiting
Phase 1Phase 2

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Endometrial CancerAdvanced Solid TumorDiffuse Large B Cell Lymphoma+5 more
Novartis Pharmaceuticals275 enrolled60 locationsNCT04104776
Recruiting
Phase 1

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

Lymphoma, T-Cell
GC Cell Corporation48 enrolled3 locationsNCT06699771
Recruiting
Phase 1

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Hodgkin LymphomaAMLMDS+8 more
Therapeutic Advances in Childhood Leukemia Consortium54 enrolled31 locationsNCT05476770
Recruiting
Phase 1Phase 2

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Lymphoma, T-Cell
University of Virginia148 enrolled1 locationNCT03161223